Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

o discuss the third quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619‐6250 (international), participant code 36014873. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: projected change in 2013 cash, cash equivalents, and marketable securities and expected year-end cash, cash equivalents, and marketable securities balance; the potential for, and timing of, the approval of a Contrave Marketing Authorization Application (MAA) in the European Union (EU); the probability of the interim analysi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014   Decision Resources Group finds ... anemic chronic kidney disease non-dialysis (CKD-ND) patients are ... medication. In addition, one-year persistency is similar between ... Other key findings from the report entitled ... Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
(Date:9/30/2014)... DIEGO , Sept. 30, 2014   ... developing a minimally invasive real-time 3D Cardiac Chamber Imaging ... that cause and / or sustain complex cardiac arrhythmias, ... $26.2M financing to continue developing its imaging/mapping system as ... The financing will allow Acutus Medical to complete work ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Water Street Healthcare Partners , a strategic private equity ... it has acquired MarketLab, Inc.  Water Street,s ... specialty healthcare distribution sector.  The acquisition expands Water Street,s ... life sciences, medical devices and services to 13. ...
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... that it was granted three new patents by State ... ("SIPO"). The patent awards were related to the design ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3
(Date:9/30/2014)... is the leading cause of cancer death in women, ... many medical professionals encourage women to get mammograms, even ... minority of suspicious mammograms actually leads to a cancer ... for women and their familiesnot to mention the time, ... biopsies. , Recently, a different type of test, ...
(Date:9/30/2014)... September 30, 2014 Keystone Symposia will convene ... first in its 2014-15 Global Health Series on ... Sheraton Seattle Hotel immediately following the conclusion of ... four-day conference is part of the Keystone Symposia Global ... Foundation, which has also funded travel awards for 36 ...
(Date:9/30/2014)... 30, 2014 A new study ... studied the impact of stress on metabolism after eating a ... fries from a fast food restaurant, about 930 calories and ... for 20 minutes every hour for 7 hours, conducting the ... women who had experienced a stressful event in their lives ...
(Date:9/30/2014)... September 30, 2014 Integrated Medicine ... is opening another new medical specialty practice through a ... Cardiology will be located within the company’s Shrewsbury ... and Dr. Isaac Tawfik of American Heart Center, P.C., ... new practice will offer Integrated Medicine Alliance patients top ...
(Date:9/30/2014)... by UC Irvine immunologists reveals new information about how ... process that determines how the body,s ability to fight ... Nature Immunology , neurology professor Dr. Michael Demetriou, postdoctoral ... describe a critical mechanism underlying how T cells are ... T cell is a type of blood cell called ...
Breaking Medicine News(10 mins):Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UCI study uncovers important process for immune system development 2
... combat death, heart attack and repeat procedures .,A recent ... of drug-coated stents on patients.// ,The study ... arteries who were treated with drug-eluting stents. An additional ... metal stents. ,Results of the one-year study ...
... studies have shown about 20 percent to 30 percent ... //either as bullies or as those attacked by bullies. ... they both bully others and are victims of bullies. ... than their peers who aren’t involved in bullying. However, ...
... study finds even flying in business class can put ... during long flights.// ,The link between blood ... during World War II, when doctors noticed a rise ... deck chairs in London air raid shelters. The association ...
... believe they’ve found a simple new test to detect ... ,In a report published in this week’s ... analysis of a person’s urine., ,Kidney cancer accounts ... cases were identified in the United States in 2003. ...
... and dieticians have been found effective in lowering total ... work only when these health professionals are able to ... program in which patients received their medications from their ... on factors aimed at improving their cardiovascular health. The ...
... procedure using less energy than the standard electrocautery may ... ,During a tonsillectomy using the electrocautery method, ... to control bleeding during the procedure. The microdissection needle ... which means less trauma to surrounding tissue., ,Researchers ...
Cached Medicine News:
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
... determines osmolality at room temperature with the ... get are cryoscopic artifacts due to high ... interfere with freezing point determinations. The superbly ... Vapro osmometer has a much broader range ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... IMMULITE 2000 assays ... with the IMMULITE 2000, ... access immunoassay analyzer. IMMULITE ... through centralization, and a ...
Medicine Products: